Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, CureVac N.V’s stock clocked out at $5.4, down -0.74% from its previous closing price of $5.44. In other words, the price has decreased by -$0.74 from its previous closing price. On the day, 0.97 million shares were traded. CVAC stock price reached its highest trading level at $5.45 during the session, while it also had its lowest trading level at $5.4.
Ratios:
To gain a deeper understanding of CVAC’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.57 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.62. For the most recent quarter (mrq), Quick Ratio is recorded 7.65 and its Current Ratio is at 7.65. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On April 25, 2024, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $12 to $4. On June 08, 2023, SVB Securities started tracking the stock assigning a Outperform rating and target price of $13.SVB Securities initiated its Outperform rating on June 08, 2023, with a $13 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 07 ’25 when Thaminda Ramanayake bought 6,986 shares for $3.34 per share.
Myriam Mendila bought 17,839 shares of CVAC for $88,019 on Jan 07 ’25. On Jan 07 ’25, another insider, Pierre Kemula, who serves as the affiliate of the company, bought 51,523 shares for $4.93 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CVAC now has a Market Capitalization of 1215934208 and an Enterprise Value of 859261824. As of this moment, CureVac’s Price-to-Earnings (P/E) ratio for their current fiscal year is 5.99. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.12 while its Price-to-Book (P/B) ratio in mrq is 1.74. Its current Enterprise Value per Revenue stands at 1.683 whereas that against EBITDA is 3.455.
Stock Price History:
The Beta on a monthly basis for CVAC is 2.53, which has changed by 0.64634144 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, CVAC has reached a high of $5.72, while it has fallen to a 52-week low of $2.37. The 50-Day Moving Average of the stock is -0.77%, while the 200-Day Moving Average is calculated to be 38.41%.
Shares Statistics:
It appears that CVAC traded 1.23M shares on average per day over the past three months and 843830 shares per day over the past ten days. A total of 225.16M shares are outstanding, with a floating share count of 95.50M. Insiders hold about 57.59% of the company’s shares, while institutions hold 5.29% stake in the company. Shares short for CVAC as of 1753920000 were 741686 with a Short Ratio of 0.60, compared to 1751241600 on 891128. Therefore, it implies a Short% of Shares Outstanding of 741686 and a Short% of Float of 0.66000004.
Earnings Estimates
The current market rating for CureVac N.V (CVAC) reflects the collective analysis of 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.07 and low estimates of -$0.07.
Analysts are recommending an EPS of between -$0.26 and -$0.71 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$0.45, with 5.0 analysts recommending between -$0.24 and -$0.73.
Revenue Estimates
A total of 7 analysts have provided revenue estimates for CVAC’s current fiscal year. The highest revenue estimate was $127.55M, while the lowest revenue estimate was $900k, resulting in an average revenue estimate of $69.05M. In the same quarter a year ago, actual revenue was $535.2M
